{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:54:51Z","timestamp":1777600491402,"version":"3.51.4"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Myasthenia gravis is an autoimmune disease mediated by B cells and is associated with acetylcholine receptor (AChR) and muscle-specific receptor tyrosine kinase (MuSK) antibodies in the postsynaptic membrane at the neuromuscular junction. The presence of both antibodies in the serum of patients with myasthenia gravis has been rarely reported. Case description: A 9-year-old girl was admitted to our hospital with the chief complaints of reduced facial expression for 3 months and unclear speech and choking from drinking water for 2 months. The diagnosis of generalized myasthenia gravis was made based on clinical manifestations, repetitive electrical nerve stimulation, neostigmine tests, specific antibody tests and other auxiliary examinations. We found the rare coexistence of two key antibodies (anti-AChR and anti-MuSK antibodies) in the patient's serum. The patient experienced myasthenic crisis and received respiratory support even though she was taking prednisone therapy. Due to the poor response to treatment with pyridostigmine bromide, glucocorticoids and IVIG, we administered rituximab therapy, and she responded well and achieved clinical remission. This suggests that clinicians should pay more attention to atypical cases and antibody detection. Rituximab should be considered when conventional treatment fails.<\/jats:p>","DOI":"10.3389\/fped.2022.788353","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T18:18:31Z","timestamp":1652293111000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Juvenile Generalized Myasthenia Gravis With AChR and MuSK Antibody Double Positivity: A Case Report With a Review of the Literature"],"prefix":"10.3389","volume":"10","author":[{"given":"XiuShan","family":"Ge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CuiJie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YueHua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XinHua","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DanYu","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HongJun","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2014.05.001","article-title":"Myasthenia Gravis: paradox versus paradigm in autoimmunity","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun."},{"key":"B3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1055\/s-0038-1676514","article-title":"Muscle-specific kinase autoimmune myasthenia gravis: report of a pediatric case and literature review","volume":"50","author":"Younes","year":"2019","journal-title":"Neuropediatrics."},{"key":"B4","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1212\/01.wnl.0000267694.45244.f4","article-title":"Anti-musk antibody after thymectomy in a previously seropositive myasthenic child","volume":"69","author":"Saulat","year":"2007","journal-title":"Neurology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.nmd.2013.07.010","article-title":"Muscle specific kinase autoimmune myasthenia gravis in children: a case series","volume":"23","author":"Skjei","year":"2013","journal-title":"Nov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1007\/s00415-009-5215-2","article-title":"Juvenile seropositive myasthenia gravis with anti-MuSK antibody after thymectomy","volume":"256","author":"Kostera-Pruszczyk","year":"2009","journal-title":"J Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1007\/s00415-012-6661-9","article-title":"Clinically biphasic myasthenia gravis with both AChR and MuSK antibodies","volume":"259","author":"Rajakulendran","year":"2012","journal-title":"J Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jneuroim.2008.05.032","article-title":"MuSK-antibody positive myasthenia gravis: questions from the clinic","volume":"201","author":"Sanders","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.nmd.2020.03.012","article-title":"AChR myasthenia gravis switching to MuSK or double antibody positive myasthenia gravis in two children and literature review","volume":"30","author":"Lu","year":"2020","journal-title":"Neuromuscul Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1055\/s-0036-1586265","article-title":"Myasthenia gravis","volume":"36","author":"Drachman","year":"2016","journal-title":"Semin Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"13928","DOI":"10.1038\/srep13928","article-title":"Collagen Q and anti-MuSK autoantibody competitively suppress agrin\/LRP4\/MuSK signaling","volume":"5","author":"Otsuka","year":"2015","journal-title":"Sci Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","article-title":"MuSK autoantibodies in myasthenia gravis detected by cell based assay\u2013a multinational study","volume":"284","author":"Tsonis","year":"2015","journal-title":"J Neuroimmunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/CH-151999","article-title":"Expression of nicotinic acetylcholine receptor subunits in HEp-2 cells for immunodetection of autoantibody specificities in sera from Myasthenia gravis patients","volume":"61","author":"George","year":"2015","journal-title":"Clin Hemorheol Microcirc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri724","article-title":"Epitope spreading in immune-mediated diseases: implications for immunotherapy","volume":"2","author":"Vanderlugt","year":"2002","journal-title":"Nat Rev Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1749-6632.1998.tb10948.x","article-title":"Epitope spreading in experimental autoimmune myasthenia gravis","volume":"841","author":"Agius","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review","volume":"91","author":"Di Stefano","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.788353\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T18:18:33Z","timestamp":1652293113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.788353\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":18,"alternative-id":["10.3389\/fped.2022.788353"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.788353","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]},"article-number":"788353"}}